April 8, 2021 7:23am
Is an old-fashioned way of asking - What do we have here (in the sector)? or What's the situation (in this market)?
Pre-open indications: 7 BUYs, 2 SELLs and 1 Maintain SELL
Mentions: BSTG, ADVM, AGTC, CRSP, EDIT, FATE, GBT, KDNY, SGMO, VYGR
If you’re looking for sector intel, ideas and opinions or Insight in a volatile climate, RMi defines the mitigating factors of share pricing!
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Dow futures are down -0.00% (-1 point), S&P futures are UP +0.34% (+14 points) and NASDAQ futures are UP +0.87% (+118 points)
Futures were moderately higher in the pre-open on Thursday, processing to a mixed and higher session
European stocks climbed boosted by the announcements from the U.K. and European medicines regulators on Wednesday regarding the AstraZeneca/University of Oxford Covid vaccine.
Asia-Pacific mostly rose after the S&P 500 nudged higher to a record closing high overnight with the MSCI’s index of Asia-Pacific shares outside Japan rising +0.46%.
Data Docket: The Labor Department’s latest update on the number of Americans filing for unemployment benefits for the first time. Economists expect first-time claims to total 694,000 during the week ended April 3.
Henry’omics:
Investors seemed pacified by the Fed’s latest meeting minutes, which showed that officials plan to keep the pace of asset purchases the same for some time as the central bank works to support stable prices and maximum employment. <CNBC>
Wednesday’s evening’s recap: “barely any distance in the upside” … https://www.regmedinvestors.com/articles/11854
- The Nasdaq closed DOWN -9.54 points (-0.07%);
- The IBB closed down -1.79% and XBI closed down -2.41%
- Sector volume was LOW with 0 of the 3-upside having higher than the 3-month average volume with the volume of 4 of 30-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -0.96 points or -5.30% at 17.16
- Wednesday’s percentage (%) of the 3-upside were +0.12% (MESO) to +5.35% (SLDB) while the 30-downside ranges from -0.13% (VCEL) to -22.80% (FIXX);
Q2/21 and April: 2 negative and 2 positive closes
Q1/21: March: 10 positive, 12 negative and 1 neutral closes
February: 9 positive, 10 negative closes and 1 holiday
January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
Biostage (BSTG): Questions continue … Maintaining Sell
Biostage (BSTG) closed flat at $1.25 with 967 shares traded after Tuesday’s -$0.05 to $1.25 with 2008 shares traded, Monday’s -$0.04 to $1.30 with 2401 shares traded and last Thursday’s flat at 1.34 with 26 shares traded.
Question#1: HOW many executives or management “team members” remain at the company? Is the website truthful and up-to-date of those WHO have left for other positions?
MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.
BUY from SELL:
Adverum Biotechnologies (ADVM) closed down -$0.28 to $9.61 after Tuesday’s $9.89, Monday’s $10.56 and last Thursday’s $10.08 with a positive +$0.79 or +8.22% aftermarket indication.
Applied Genetic Technologies (AGTC) closed down -$0.29 to $4.45 after Tuesday’s $4.74, Monday’s $4.99 and last Thursday’s $5.23 with a positive +$0.19 or +4.27% pre-market indication.
Editas Medicine (EDIT) closed down -$2.24 to $40.40 after Tuesday’s -$0.22 to $42.64, Monday’s +$0.03 to $42.86 and last Thursday’s +$0.93 to $42.83 with a positive +$0.15 or +0.37% pre-market indication.
Sangamo Therapeutics (SGMO) closed down -$0.61 to $11.24 after Tuesday’s -$0.79 to $11.85 and Monday’s $12.64 with a positive +$0.58 or +5.16% pre-market indication.
Maintaining SELL;
Chinook Therapeutics (KDNY) closed down -$0.08 to $14.74 after Tuesday’s $14.83, Monday’s $15.27 after last Thursday’s $15.50 with a negative -$0.29 or -1.97% aftermarket indication post earnings release.
Fate Therapeutics (FATE) closed down -$4.40 to $75.70 after Tuesday’s-$3.56 to $80.10 and Monday’s -$1.75 with a negative -$0.70 or -0.92% aftermarket indication.
Maintain BUY:
CRISPR Therapeutics (CRSP) closed down -$3.10 to $118.53 after Tuesday’s -$0.36 to $121.63, Monday’s +$2.58 to $121.99 and last Thursday’s -$2.44 to $119.41 with a positive +$1.60 or +0.89% pre-market indication.
Global Blood Therapeutics (GBT) closed down -$0.18 to $42.28 after Tuesday’s $42.46 and Monday’s $42.49 with a positive +$0.72 or +1.70% pre-market indication on news of The Lancet Hematology publishing the complete analysis of 72-week data from the Phase 3 HOPE Study of Oxbryta® (voxelotor) tablets in patients with sickle cell disease (SCD). The results showed significant and sustained improvement in hemoglobin levels, reduction in hemolysis and improved overall health status in patients treated with Oxbryta. These findings support the long-term use of Oxbryta to reduce hemolytic anemia and hemolysis in SCD, potentially mitigating life-threatening complications of the condition.
Voyager Therapeutics (VYGR) closed down -$0.14 to $4.77 after Tuesday’s -0.13 to $4.91, Monday’s $5.04 with a positive +$0.03 or +0.63% aftermarket indication
The BOTTOM LINE: I’m maintaining my stance, “blowing on the dice” today before the “throw” into today’s session.
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
